Skip to main content
OpenTrials
Completed

NCT Number: NCT04915781

Tobacco Use and COVID-19 Incidence in the Finnish General Population

This is an observational study of participants in three general population health surveys (FinSote 2018, 2019, 2020) who are followed up until the incidence of SARS-CoV-2 infection or end of follow-up. The primary objective is to examine the association between tobacco use and the risk of SARS-CoV-2 infection in a general population sample in Finland.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Tobacco use, as a leading risk factor of death and disability due to respiratory diseases, was expected to increase the risk of SARS-CoV-2 infection and COVID-19 deaths. Earlier epidemiological studies, however, showed that smokers were underrepresented among patients hospitalized due to COVID-19. The most recent meta-analysis has confirmed these early findings, showing that current smokers had lower risk of SARS-CoV-2 infection than never smokers (Relative risk 0.71, 95% Credible interval 0.61; 0.82). A majority of these studies are based on samples of hospitalized patients, tested population or specific population groups, which might not represent the general population. In addition, data on tobacco use has been primarily collected from electronic health records or retrospectively and therefore prone to misclassification and information bias.

A message of a protective effect of tobacco use could undermine public health efforts to curb its use and reduce the perception of harm in the general population. Studies with general population samples and prospective data collection are thus urgently needed.

The aim of the study is to examine the association between tobacco use and the risk of SARS-CoV-2 infection. We will explore several forms of tobacco use (smoking, moist smokeless tobacco and e-cigarettes) and investigate whether introducing a potential collider bias by adjusting for mediating risk factors (alcohol use, physical activity and obesity) could have explained earlier results. We will use data from a prospective cohort study of nationally representative health surveys in Finland linked to SARS-CoV-2 incidence data, which is less subject to collider and recall bias than previous case-control studies.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Permanent residents of Finland
  • Registered in the Population Register at the moment of sampling
  • Aged 20 and over
  • Participated in the FinSote surveys in 2018, 2019 or 2020

Exclusion criteria

  • Temporary residents in Finland or tourists
  • Age less than 20 years old
  • Did not participate in FinSote surveys in 2018, 2019 and 2020

Treatment and study plan

Not applicable, this is an observational study

Other

Not applicable, this is an observational study

Primary outcomes

  1. Incidence of SARS-CoV-2 infection

    Time frame: Baseline until SARS-CoV-2 infection or April 30, 2021

    Incidence is the detection of a new SARS-CoV-2 infection with RT-PCR or a COVID-19 syndrome diagnosed by a physician from baseline to April 30, 2021

Sponsors and collaborators

Lead sponsor

Finnish Institute for Health and Welfare

Other Gov

Collaborators

  • Karolinska Institutet
  • Norwegian Institute of Public Health

Registry information

Official study title

Tobacco Use and Incidence of SARS-CoV-2 Infection in the Finnish General Population

Acronym: Tobrisk-CoV

Important dates

Study start
2017
Primary completion
2021
Study completion
2021
First posted
Jun 7, 2021
Registry last updated
Jun 22, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.